Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide

Abaloparatide (ABL) is a 34-amino acid peptide designed to be a selective activator of the parathyroid hormone receptor type 1 signaling pathway. In the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE), subcutaneous ABL reduced the risk of new vertebral, nonvertebral, clinical, and maj...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Calcif Tissue Int
Главные авторы: Reginster, Jean-Yves, Hattersley, Gary, Williams, Gregory C., Hu, Ming-yi, Fitzpatrick, Lorraine A., Lewiecki, E. Michael
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2018
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182596/
https://ncbi.nlm.nih.gov/pubmed/29951742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00223-018-0450-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы